Promising combo study halted early: only 4 patients enrolled
NCT ID NCT00776373
First seen Nov 05, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tested whether adding the drug rapamycin to high-dose chemotherapy could help people with aggressive blood cancers that had come back or not responded to treatment. The trial was open to adults aged 18 to 65 with certain types of leukemia or lymphoma. Only 4 people took part before the study was stopped early, so we have very limited information on how well it worked or what side effects occurred.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19066, United States
Conditions
Explore the condition pages connected to this study.